Hyperfine, Inc. (NASDAQ: HYPR)

Sector: Healthcare Industry: Medical Devices CIK: 0001833769
Market Cap 84.73 Mn
P/B 3.15
P/E -2.12
P/S 8.00
ROIC (Qtr) -129.62
Div Yield % 0.00
Rev 1y % (Qtr) -5.65
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00
Add ratio to table...

About

Hyperfine, Inc., a health technology company, has developed a revolutionary portable, ultra-low-field magnetic resonance (MR) brain imaging system, the Swoop system. The company's mission is to transform patient care globally through accessible, affordable, and clinically relevant brain imaging. With its innovative technology, Hyperfine aims to make brain MR imaging available to patients worldwide, particularly in low-resource settings where conventional MRI scanners are not readily available. The Swoop system is a portable, user-friendly device...

Read more

Investment thesis

Bull case

  • Tangible assets of 41.51M provide exceptional 17.23x coverage of deferred revenue 2.41M, showing strong service capability backing.
  • Tangible assets of 41.51M provide robust 6.47x coverage of other current liabilities 6.41M, indicating strong asset backing.
  • Cash reserves of 22.03M provide robust 2.17x coverage of current liabilities 10.17M, indicating strong short-term solvency.
  • Strong cash position of 22.03M provides 3.44x coverage of other current liabilities 6.41M, indicating excellent liquidity.
  • Cash reserves of 22.03M provide solid 10.68x coverage of other non-current liabilities 2.06M, indicating strong liquidity.

Bear case

  • Investment activities of (1.13M) provide weak support for R&D spending of 18.73M, which is -0.06x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of (31.10M) provides insufficient coverage of deferred revenue obligations of 2.41M, which is -12.91x, raising concerns about future service delivery capabilities.
  • The company's operating cash flow of (31.10M) shows concerning coverage of stock compensation expenses of 3.16M, with a -9.83 ratio indicating potential earnings quality issues.
  • Free cash flow of (32.23M) provides weak coverage of capital expenditures of 1.13M, with a -28.52 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (40.05M) show weak coverage of depreciation charges of 1.04M, with a -38.40 ratio indicating high capital intensity and potential reinvestment needs.

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 173.80 Bn 32.73 5.47 12.94 Bn
2 SYK Stryker Corp 141.15 Bn 43.48 5.62 15.86 Bn
3 MDT Medtronic plc 123.47 Bn 25.92 3.55 29.10 Bn
4 BSX Boston Scientific Corp 112.80 Bn 38.92 5.62 11.44 Bn
5 EW Edwards Lifesciences Corp 45.66 Bn 33.38 7.76 0.70 Bn
6 DXCM Dexcom Inc 27.52 Bn 32.91 5.90 1.34 Bn
7 STE STERIS plc 24.13 Bn 34.08 4.14 2.05 Bn
8 PODD Insulet Corp 17.33 Bn 70.38 6.87 1.01 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 1.42 2.13
EV to Cash from Ops. EV/CFO -1.90 2.75
EV to Debt EV to Debt 0.00 17.25
EV to EBIT EV/EBIT -1.48 2.89
EV to EBITDA EV/EBITDA -1.51 4.53
EV to Free Cash Flow [EV/FCF] EV/FCF -1.84 29.36
EV to Market Cap EV to Market Cap 0.70 25.09
EV to Revenue EV/Rev 5.58 32.80
Price to Book Value [P/B] P/B 3.15 4.73
Price to Earnings [P/E] P/E -2.12 -2.04
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 40.22
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 1.59
Dividend per Basic Share Div per Share (Qtr) 0.00 0.10
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.37
Interest Coverage Interest Coverage 0.00 196.93
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) -78.52 -152.08
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -52.09 8,476.58
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 -0.44
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 2.35 -792.16
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 9.08 3.79
EBIT Growth (1y) % EBIT 1y % (Qtr) 2.35 -301.80
EBT Growth (1y) % EBT 1y % (Qtr) 2.35 -121.44
EPS Growth (1y) % EPS 1y % (Qtr) 8.77 -87.51
FCF Growth (1y) % FCF 1y % (Qtr) 21.36 10.43
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) -19.90 38.21
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.26 0.55
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.02
Cash Ratio Cash Ratio (Qtr) 2.17 1.80
Current Ratio Curr Ratio (Qtr) 3.63 4.18
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 1.20
Interest Cover Ratio Interest Cover Ratio 0.00 196.93
Times Interest Earned Times Interest Earned 0.00 196.93
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) -368.30 -2,396.63
EBIT Margin % EBIT Margin % (Qtr) -378.17 -2,478.60
EBT Margin % EBT Margin % (Qtr) -378.17 -2,690.42
Gross Margin % Gross Margin % (Qtr) 46.10 30.80
Net Profit Margin % Net Margin % (Qtr) -378.20 -2,821.53